Pfizer Gross Margin 2010-2023 | PFE
Current and historical gross margin for Pfizer (PFE) over the last 10 years. The current gross profit margin for Pfizer as of December 31, 2023 is %.
| Pfizer Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-12-31 |
$58.50B |
$33.54B |
57.34% |
| 2023-09-30 |
$68.54B |
$41.50B |
60.55% |
| 2023-06-30 |
$77.94B |
$54.11B |
69.42% |
| 2023-03-31 |
$92.95B |
$63.71B |
68.54% |
| 2022-12-31 |
$100.33B |
$65.99B |
65.77% |
| 2022-09-30 |
$99.88B |
$65.45B |
65.53% |
| 2022-06-30 |
$101.28B |
$62.98B |
62.18% |
| 2022-03-31 |
$92.43B |
$55.79B |
60.35% |
| 2021-12-31 |
$81.29B |
$50.47B |
62.08% |
| 2021-09-30 |
$68.88B |
$45.08B |
65.45% |
| 2021-06-30 |
$55.12B |
$39.25B |
71.21% |
| 2021-03-31 |
$46.08B |
$35.38B |
76.78% |
| 2020-12-31 |
$41.65B |
$33.17B |
79.63% |
| 2020-09-30 |
$32.07B |
$25.85B |
80.62% |
| 2020-06-30 |
$34.47B |
$27.66B |
80.24% |
| 2020-03-31 |
$37.87B |
$30.31B |
80.03% |
| 2019-12-31 |
$40.91B |
$32.85B |
80.31% |
| 2019-09-30 |
$40.22B |
$31.79B |
79.05% |
| 2019-06-30 |
$40.84B |
$32.32B |
79.14% |
| 2019-03-31 |
$41.04B |
$32.18B |
78.42% |
| 2018-12-31 |
$40.83B |
$31.84B |
77.99% |
| 2018-09-30 |
$53.37B |
$41.94B |
78.59% |
| 2018-06-30 |
$53.24B |
$41.66B |
78.25% |
| 2018-03-31 |
$52.67B |
$41.35B |
78.50% |
| 2017-12-31 |
$52.55B |
$41.32B |
78.63% |
| 2017-09-30 |
$52.47B |
$41.29B |
78.68% |
| 2017-06-30 |
$52.35B |
$40.92B |
78.17% |
| 2017-03-31 |
$52.60B |
$40.66B |
77.30% |
| 2016-12-31 |
$52.82B |
$40.50B |
76.67% |
| 2016-09-30 |
$53.24B |
$40.72B |
76.48% |
| 2016-06-30 |
$52.29B |
$40.63B |
77.71% |
| 2016-03-31 |
$50.99B |
$40.33B |
79.09% |
| 2015-12-31 |
$48.85B |
$39.20B |
80.25% |
| 2015-09-30 |
$47.92B |
$38.98B |
81.35% |
| 2015-06-30 |
$48.20B |
$39.11B |
81.14% |
| 2015-03-31 |
$49.12B |
$39.75B |
80.92% |
| 2014-12-31 |
$49.61B |
$40.03B |
80.69% |
| 2014-09-30 |
$50.05B |
$40.38B |
80.68% |
| 2014-06-30 |
$50.33B |
$40.74B |
80.95% |
| 2014-03-31 |
$50.53B |
$41.16B |
81.46% |
| 2013-12-31 |
$51.58B |
$42.00B |
81.42% |
| 2013-09-30 |
$50.88B |
$41.69B |
81.95% |
| 2013-06-30 |
$51.19B |
$41.98B |
82.02% |
| 2013-03-31 |
$52.18B |
$42.84B |
82.10% |
| 2012-12-31 |
$54.66B |
$44.84B |
82.03% |
| 2012-09-30 |
$53.25B |
$43.99B |
82.61% |
| 2012-06-30 |
$56.90B |
$46.54B |
81.80% |
| 2012-03-31 |
$59.42B |
$47.87B |
80.56% |
| 2011-12-31 |
$61.04B |
$48.54B |
79.52% |
| 2011-09-30 |
$65.06B |
$51.27B |
78.81% |
| 2011-06-30 |
$64.44B |
$50.28B |
78.02% |
| 2011-03-31 |
$65.09B |
$50.81B |
78.06% |
| 2010-12-31 |
$65.17B |
$50.38B |
77.31% |
| 2010-09-30 |
$65.50B |
$50.32B |
76.82% |
| 2010-06-30 |
$61.13B |
$47.95B |
78.44% |
| 2010-03-31 |
$54.98B |
$43.73B |
79.53% |
| 2009-12-31 |
$49.27B |
$40.81B |
82.83% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.772B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
